India
· Delayed Price · Currency is INR Dr. Reddy's Laboratories Statistics
Total Valuation
Dr. Reddy's Laboratories has a market cap or net worth of INR 1.12 trillion. The enterprise value is 1.06 trillion.
| Market Cap | 1.12T |
| Enterprise Value | 1.06T |
Important Dates
The next estimated earnings date is Tuesday, November 5, 2024.
| Earnings Date | Nov 5, 2024 |
| Ex-Dividend Date | Jul 16, 2024 |
Share Statistics
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.20% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 119.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.89 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.10, with an EV/FCF ratio of 42.71.
| EV / Earnings | 19.06 |
| EV / Sales | 3.67 |
| EV / EBITDA | 13.10 |
| EV / EBIT | 16.11 |
| EV / FCF | 42.71 |
Financial Position
The company has a current ratio of 2.55, with a Debt / Equity ratio of 10.41.
| Current Ratio | 2.55 |
| Quick Ratio | 1.66 |
| Debt / Equity | 10.41 |
| Debt / EBITDA | 0.38 |
| Debt / FCF | 1.24 |
| Interest Coverage | 33.85 |
Financial Efficiency
Return on equity (ROE) is 20.59% and return on invested capital (ROIC) is 14.06%.
| Return on Equity (ROE) | 20.59% |
| Return on Assets (ROA) | 10.93% |
| Return on Capital (ROIC) | 14.06% |
| Revenue Per Employee | 10.67M |
| Profits Per Employee | 2.05M |
| Employee Count | 27,048 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 1.95 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +23.03% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +23.03% |
| 50-Day Moving Average | 6,805.58 |
| 200-Day Moving Average | 6,266.54 |
| Relative Strength Index (RSI) | 50.94 |
| Average Volume (20 Days) | 426,703 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Dr. Reddy's Laboratories had revenue of INR 288.51 billion and earned 55.58 billion in profits. Earnings per share was 333.26.
| Revenue | 288.51B |
| Gross Profit | 170.40B |
| Operating Income | 65.60B |
| Pretax Income | 72.23B |
| Net Income | 55.58B |
| EBITDA | 79.54B |
| EBIT | 65.60B |
| Earnings Per Share (EPS) | 333.26 |
Balance Sheet
The company has 94.63 billion in cash and 30.68 billion in debt, giving a net cash position of 63.95 billion.
| Cash & Cash Equivalents | 94.63B |
| Total Debt | 30.68B |
| Net Cash | 63.95B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 294.63B |
| Book Value Per Share | 1,769.05 |
| Working Capital | 163.52B |
Cash Flow
In the last 12 months, operating cash flow was 42.68 billion and capital expenditures -17.87 billion, giving a free cash flow of 24.81 billion.
| Operating Cash Flow | 42.68B |
| Capital Expenditures | -17.87B |
| Free Cash Flow | 24.81B |
| FCF Per Share | n/a |
Margins
Gross margin is 59.06%, with operating and profit margins of 22.74% and 19.26%.
| Gross Margin | 59.06% |
| Operating Margin | 22.74% |
| Pretax Margin | 25.04% |
| Profit Margin | 19.26% |
| EBITDA Margin | 27.57% |
| EBIT Margin | 22.74% |
| FCF Margin | 8.60% |
Dividends & Yields
Dr. Reddy's Laboratories does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | 11.96% |
| Buyback Yield | -0.20% |
| Shareholder Yield | -0.20% |
| Earnings Yield | 4.94% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on August 28, 2006. It was a forward split with a ratio of 2.
| Last Split Date | Aug 28, 2006 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Dr. Reddy's Laboratories has an Altman Z-Score of 7.44.
| Altman Z-Score | 7.44 |
| Piotroski F-Score | n/a |